Preclinical studies phases

Most recently, a phase-I-study defined a dose of 13-ris-retinoic acid that was tolerable in patients after myeloablative therapy, and a phase-III-trial showed that postconsolidation therapy with 13-cis-retinoic acid improved EFS for patients with high-risk neuroblastoma [7]. Preclinical studies in neuroblastoma indicate that ATRA or 13-cw-RA can antagonize cytotoxic chemotherapy and radiation, such that use of 13-cis-RA in neuroblastoma is limited to maintenance after completion of cytotoxic chemotherapy and radiation. It is likely that recurrent disease seen during or after 13-cis-RA therapy in neuroblastoma is due to tumor cell resistance to retinoid-mediated differentiation induction. Studies in neuroblastoma cell lines resistant to 13-cw-RA and ATRA have shown that they can be sensitive, and in some cases collaterally hypersensitive, to the cytotoxic retinoid fenretinide. Here, fenretinide induces tumor cell cytotoxicity rather than differentiation, acts independently from RA receptors, and in initial phase-I-trials has been well tolerated. Clinical trials of fenretinide, alone and in combination with ceramide modulators, are in development. 

Preclinical studies Animal studies that support Phase I safety and tolerance studies and must comply with Good Laboratory Practice (GLP). Other preclinical studies are done in discovery research laboratories to support drug efficiency claims. 

Research (on medicines). Numerous definitions of research are used both in the literature and among scientists. In the broadest sense, research in the pharmaceutical industry includes all processes of medicine discovery, preclinical and clinical evaluation, and technical development. In a more restricted sense, research concentrates on the preclinical discovery phase, where the basic characteristics of a new medicine are determined. Once a decision is reached to study the medicine in humans to evaluate its therapeutic potential, the compound passes from the research to the development phase. 

Alzheimer s Disease The vaccine being tested contains a small protein called jS-amyloid (AjS). This protein forms abnormal deposits, or plaques, in the brains of people with Alzheimer s disease. Researchers believe that Kji deposition causes loss of mental function by killing the brain neurons. The strategy of Aji vaccination is to stimulate the immune system to clean up plaques and prevent further A deposits. Although preclinical and Phase I studies showed the potential of the vaccine, the Phase II clinical trial was halted because 15 of 360 patients developed severe brain inflammation. Further studies showed that the A did generate the desired... 

Alios Therapeutics Inc. was then able to proceed through a phase-one study on the basis of the basic and preclinical studies for only 2 million. This is perhaps a record for a new drug. The following graph prepared by the former Alios CEO, Stephen Hoffman, compared the cost of development of RSR 13 to the blood substitute companies that also sought to increase oxygen delivery in vivo (Figure 17.4). 

Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880) correlation with preclinical studies. Cancer Chemother Rep 1972 56(4) 515-521. 

Huang et al. [96] developed a method for the enantiomeric purity determination of (6 )-ornidazole in raw material and injection solution that was used in an preclinical study. In this publication, a mobile phase of n-hexane, MeOH, and 2-PrOH (95 4 1) was used with a Chiralcel OB-H column. No chiral impurity (/ )-ornidazole was detected above the LOD (0.05%) in either the raw material or the injection solution (see Figure 17.4D and E). The separation of the racemate is presented in Figure 17.4A, and the minor peak in Figure 17.4B corresponds to an enantiomeric impurity of 0.5%. 

The clinical drug development process required by the US FDA, arguably the most stringent in the world, starts with the investigational new drug (IND) application prior to human testing. It reveals information about all known compounds to be used and includes the description of the clinical research plan for the product as well as the protocol for phase I studies. Preclinical study results also need to be revealed. 

Preclinical studies of ziprasidone indicate that it also has a low propensity to induce EPS, which was confirmed in subsequent phase II and III studies. Furthermore, the motor symptoms evoked by ziprasidone were seldom sufficiently troublesome to warrant anticholinergic medication. In one phase III trial, not more than 25% of patients receiving 160 mg/day were prescribed an anticholinergic at any time during the 6-week treatment period. These results indicate that therapeutic doses of ziprasidone not only induce a low incidence of acute EPS, but when they occur, they are often mild and do not require antiparkinsonian medication (137). 

StemCells, Inc. is developing a proprietary NSC product for cellular therapy, under license from NeuroSpheres Ltd., comprising well-characterized, normal human CNS stem cells (HuCNS-SCs) from brain tissue. HuCNS-SC is currently under investigation for the potential treatment of neurodegenerative disorders, particularly BD [180367], [540074]. Preclinical studies have been performed in various animal models of CNS diseases and injuries. Data from these studies has supported the therapeutic potential of HuCNS-SCs, and the therapy has recently been approved for a phase I clinical trial for the treatment of BD [629732]. 

After choosing the lead , one may use knowledge of the receptor site to achieve potency or selectivity advantages. One may even be able to generate the lead based on knowledge of receptor structure alone (see Sections 3.2 and 3.3). Whether or not such knowledge of the receptor site is available, the methods outlined in this section can be applied in order to optimize drug properties to the point of selection for preclinical or phase 1 study. 

At present, BP 2.94 (36) is under clinical development in Phase II trials for the treatment of asthma, pneumoallergic diseases, and others. Preclinical studies in rodents clearly displayed anti-inflammatory as well as antinociceptive activity of BP 2.94 (36) given orally at low doses. These effects are mediated by inhibitory H3 receptors located on sensory C-fibres in several different tissues. In particular, capsaicin-induced plasma protein extravasation was dose-dependently inhibited in airways, digestive tract, skin, conjunctiva, urinaiy bladder, nasal mucosa, and dura mater of the rat. In the p-phenylbenzoquinone-induced writhing test in mice, BP 2.94 (36) had a pronounced antinociceptive activity similar to that of acetylsalicylic acid. This effect was significantly abolished by the H3 receptor antagonist thioperamide but not by naloxone. Furthermore, BP 2.94 (36) reduced zymosan-induced edema. This antiinflammatory effect was also abolished by thioperamide [6]. 

---